Haploidentical HSCT tolerated by patients with severe anemia

03/14/2013 | Healio

Pediatric patients with severe aplastic anemia were able to tolerate and benefit from haploidentical hematopoietic stem cell transplants, according to a study published in Biology of Blood and Marrow Transplantation. Eleven of the 12 patients who underwent the treatment showed neutrophil engraftment at a median of 10 days following the transplant, researchers said. In one primary engraftment failure case and two graft rejection cases, a second haploidentical hematopoietic stem cell transplant led to a 100% final engraftment rate, the study said. Follow-up at a median of 14.3 months showed all 12 patients were alive and no longer requiring transfusions.

View Full Article in:

Healio

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Director, Quality Regulatory Affairs
Cardinal Health
Chicago, IL
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC